TLR4 and acute myeloid leukemia: Sorted TLR4+ MSCs derived from AML patients decreased NK cell proliferation and cytotoxicity, and this effect was enhanced by the activation of the TLR4 pathway following lipopolysaccharides treatment [52, 53].